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  44 
ABSTRACT 45 
 46 
Two new cocrystals of zafirlukast with piperazine, existing in five different solid forms, have been 47 
discovered during a cocrystal screening. The crystal structure of one of these forms has been determined 48 
by single crystal X-ray diffraction, and the stability landscape of the crystalline forms of the new 49 
cocrystal has been studied. In the present article, we extend the knowledge about the solid state of this 50 
important pharmaceutical drug for the treatment of asthma by reporting the crystal structures of two new 51 
solvates (acetonitrile and butanol) and the elusive anhydrous Form X, which have been solved by single 52 







  60 
1. INTRODUCTION 61 
 62 
The design and synthesis of cocrystals of active pharmaceutical ingredients (APIs) have attracted much 63 
interest recently due to their potential ability to modify important properties of pharmaceutical materials 64 
such as solubility or stability, which can be improved with respect to the native active compound.1 Also, 65 
the investigation of polymorphism of APIs is a key issue because of its great impact not only on the 66 
chemical properties but also on the intellectual property related to the commercial exploitation of a 67 
drug.2 Cocrystals can exhibit polymorphism or pseudo-polymorphism (presence of solvent molecules in 68 
the crystal structure) in the same way as single-component crystalline solids, and thus they must be 69 
completely characterized prior to a defensive strategy, which eventually will take the form of a patent.3 70 
Moreover, cocrystallization can provide the way to increase the number of solid forms for an API 71 
through stoichiometric variations between the different components that form the cocrystal.4 72 
In this sense, the number of cocrystals with different API/coformer stoichiometries and their mutual 73 
interconversion, the presence of polymorphism, the stability of solvates, and their conversion to pure 74 
forms upon solvent removal must be known in order to design the experimental conditions for the 75 
selective preparation of the desired crystal form. 76 
Zafirlukast, (4-(5-cyclopentyloxycarbonylamino-1-methylindol-3-ylmethyl)-3-methoxy-o-toyl 77 
sulphonylbenzamide, ZF hereafter, Figure 1), is a cysteinyl leukotriene which is used to help to control 78 
the symptoms of asthma.5 ZF has been described previously to exist in five crystal modifications: the 79 
anhydrous form,6 an acetonitrile solvate,7 a methanol solvate,8 an ethanol solvate,8 and a 80 
monohydrate,6 with only the crystal structure of the last three forms already reported,8 and the crystal 81 
structure of the anhydrous form remains, so far, elusive. 82 
The anhydrous form of ZF shows relatively low bioavailability, and hence the amorphous form is 83 
selected for further development in the industry. The amorphous form of ZF has relatively good physical 84 
stability and bioavailability and is prepared by dehydration of the monohydrate form in a vacuum oven 85 
at 393 K for 24 h.9 However, amorphous ZF can convert to the monohydrate (which has low 86 
bioavailability) in the presence of water. Thus, new crystalline forms with potential improved 87 
bioavailability over the anhydrous form are attractive for this API. 88 
In this article, we present two polymorphic cocrystals of ZF with piperazine together with the 89 
description of the relative stability of its forms and the crystal structure of the 2:1 (ZF:piperazine) 90 
cocrystal. The study includes the first reported crystal structure of the anhydrous form of ZF and two 91 
novel solvate forms. A comparative analysis of the intermolecular interactions present in all four new 92 
crystal structures of this oral drug is also presented. 93 
  94 
2. MATERIALS AND METHODS 95 
 96 
2.1. Synthesis of the Different Crystal Forms. 2.1.1. Anhydrous Form X. It was obtained by slow 97 
crystallization at room temperature from a non saturated solution of ZF in IPA, pentane, heptane, 98 
cyclohexane, toluene, xylene, AcOEt, Et2O, ethylene glycol dimethyl, diisopropyl ether, or 99 
dichloromethane (m.p. 190 °C). 100 
2.1.2. Butanol Solvate. It was obtained by slow crystallization from a solution of ZF (20 mg) in BuOH 101 
(3.0 mL) at 80 °C. The solution was cooled down at room temperature in 30 min and crystals appeared 102 
after 2 days. 103 
2.1.3. Acetonitrile Solvate. It was obtained by slow crystallization from a solution of ZF (15 mg) in 104 
ACN (1.3 mL) at 50 °C. The solution was cooled down at room temperature in 30 min and crystals 105 
appeared after 2 days. 106 
2.1.4. Piperazine Cocrystal (2:1) Form A. It was obtained by slow crystallization from a solution of 107 
ZF:piperazine (1:1) in ethanol. ZF (20 mg) and piperazine (3 mg), molar ratio 1:1, were dissolved in 108 
ethanol (0.3 mL) at 60 °C. The solution was cooled down at room  temperature in 30 min and crystals 109 
appeared after 4 days (m.p. 218 °C). 110 
2.1.5. Piperazine Cocrystal (2:1) Form B. It was obtained by slurry in water at room temperature. ZF (50 111 
mg) and piperazine (11 mg), molar ratio 1:1.5, were slurred in water (0.4 mL) at room temperature 112 
during 24 h. The solid was filtered and dried under a vacuum 48 h, (m.p. 212 °C). 113 
2.1.6. Piperazine Cocrystal (1:1) Form C. It was obtained by slurry in ethanol at room temperature. ZF 114 
(75 mg) and piperazine (20 mg), molar ratio 1:2, were slurred in ethanol (0.05 mL) at room temperature 115 
during 24 h. The solid was filtered and dried under vacuum 48 h. 116 
2.1.7. Piperazine Cocrystal (1:1) Form D. It was obtained by slurry in methanol, IPA, acetonitrile, 117 
acetone, MiBK or AcOEt at room temperature. For instance, ZF (50 mg) and piperazine (11 mg), molar 118 
ratio 1:1.5, were slurred in ACN (1.0 mL) at room temperature during 24 h. The solid was filtered and 119 
dried under vacuum 48 h, (mp 181 °C). 120 
2.1.8. Piperazine Cocrystal (1:1) Toluene Solvate Form E. It was obtained by slurry in toluene at room 121 
temperature. ZF (50 mg) and piperazine (11 mg), molar ratio 1:1.5, were slurred in toluene (1.0 mL) at 122 
room temperature during 24 h. The solid was filtered and dried under vacuum 48 h, (mp 106 °C). 123 
2.2. Methods. 2.2.1. Powder X-ray Diffraction (PXRD). Powder Xray diffraction patterns were obtained 124 
on a PANalytical X’Pert PRO MPD diffractometer in transmission configuration using Cu Kα1 + 2 125 
radiation (λ = 1.5418 Å) with a focalizing elliptic mirror, a PIXcel detector working at a maximum 126 
detector’s active length of 3.347°. Capillary geometry has been used with samples placed in glass 127 
capillaries (Lindemman) of 0.5 mm of diameter measuring from 2 to 60° in 2θ, with a step size of 128 
0.026° and a total measuring time of 30 min. Flat geometry has been used for routine samples 129 
sandwiched between low absorbing films (polyester of 3.6 μm of thickness) measuring 2θ/θscans from 2 130 
to 40° in 2θ with a step size of 0.026° and a measuring time of 76 s per step. When cell indexation was 131 
required, the powder X-ray diffraction pattern was obtained using capillary geometry and soller slit of 132 
0.01 radians. The sample was placed in a capillary of 0.7 mm, and consecutive 2θ scans from 2 to 70° 133 
were measured and added. 134 
2.2.2. Single Crystal X-ray Diffraction. Two different instruments have been used. (a) MAR345 135 
diffractometer with an image plate detector was used. Intensities were collected with graphite 136 
monochromatized MoKα radiation (λ = 0.71073 Å) using a ϕ−scan technique. The structures were 137 
solved by direct methods, using the SHELXS computer program10 and refined by full-matrix least-138 
squares method with the SHELX97 computer program. 139 
(b) A D8 Venture system equipped with a multilayer monochromator and a Mo microfocus (λ = 0.71073 140 
Å) was used too. Frames were integrated with the Bruker SAINT software package using a SAINT 141 
algorithm. Data were corrected for absorption effects using the multiscan method (SADABS). The 142 
structure was solved and refined using the Bruker SHELXTL Software Package,11 a computer program 143 
for automatic solution of crystal structure and refined by fullmatrix least-squares method with ShelXle 144 
Version 4.8.0, a Qt graphical user interface for SHELXL computer program.12 145 
2.2.3. Differential Scanning Calorimetry (DSC). Differential scanning calorimetry was carried out by 146 
means of a Mettler-Toledo DSC-822e calorimeter. Experimental conditions: aluminum crucibles of 40 147 
μL volume, atmosphere of dry nitrogen with 50 mL/min flow rate, heating rate of 10 °C/min. The 148 
calorimeter was calibrated with indium of 99.99% purity. 149 
2.2.4. Thermogravimetric Analysis (TGA). Thermogravimetric analyses were performed on a Mettler-150 
Toledo TGA-851e thermobalance. Experimental conditions: alumina crucibles of 70 μL volume, 151 
atmosphere of dry nitrogen with 50 mL/min flow rate, heating rate of 10 °C/min. 152 
2.2.5. Cocrystal Screening. Screening for cocrystal formation through liquid assisted grinding 153 
experiments (LAG) was conducted by grinding 20−30 mg of a 1:1 mixture of ZF and each conformer 154 
together with one drop of different solvents using a Retsch MM 2000 grinding mill. The samples were 155 
placed in 2 mL volume stainless steel jars, along with two stainless tungsten grinding balls of 3 mm 156 
diameter. Grinding was performed for 15−30 min, with a frequency of the mill of 30 Hz. Finally, the 157 
samples were collected immediately without prior drying for PXRD analysis. The formation of a 158 
cocrystal was determined by comparing PXRD patterns of starting materials and products from cocrystal 159 
screening LAG experiments. 160 
 161 
  162 
3. RESULTS AND DISCUSSION 163 
 164 
3.1. Solid Forms Screening of ZF. Bearing in mind that only an anhydrous form has been described for 165 
ZF, we conducted a polymorph screening starting from the amorphous material in order to obtain and 166 
characterize as many forms as possible. Using a broad set of thermodynamic and kinetic crystallization 167 
conditions from a variety of solvents, we obtained evidence of solvate formation with methyletylketone, 168 
acetone, methylisobutylketone, benzyl alcohol, ammonia, acetonitrile, and butanol. However, we could 169 
only isolate in pure form the last two solvates. A summary of all experimental conditions can be found 170 
in the Supporting Information section. All forms were characterized by means of X-ray powder 171 
diffraction, DSC, and TGA. The X-ray powder diffractograms of the new solvates (compared with the 172 
anhydrous Form X) are shown in Figure 2, while Figures 3 and 4 show the DSC and the TGA curves of 173 
the different solvates, respectively. 174 
No new anhydrous polymorphs were detected. In all cases the DSC thermograms show a very similar 175 
pattern of desolvation on heating followed by the crystallization and subsequent melting of the 176 
anhydrous form. All desolvated samples were analyzed by PXRD, and the transformation into the 177 
anhydrous Form X was confirmed. 178 
3.2. Cocrystal Screening. Since ZF contains strong Hbond donor and acceptor groups, a diverse set of 179 
coformers such as amines, alcohols, and carboxylic acids, among others, were selected having 180 
acceptable toxicity profiles. Supporting Information contains the complete list of coformers tested in this 181 
study. The analysis by PXRD of the samples generated during the LAG experiments revealed that 4 out 182 
of the 25 tested coformers showed evidence of the existence of new solid phases different than any 183 
known form of ZF and the respective coformer: 3-hydroxybenzoic acid, 3,4-dihydroxybenzoic acid, 4- 184 
hexylresorcinol, and piperazine. However, although great efforts were devoted to isolate the new solid 185 
forms, only piperazine produced pure new forms suitable for further characterization and analysis. The 186 
following section describes them in detail. 187 
3.3. Crystal Structures Analysis. 3.3.1. Anhydrous Form X of Zafirlukast. Anhydrous Form X 188 
crystallizes with one molecule of ZF in the asymmetric unit forming ribbons linked  through 189 
amide−amide hydrogen-bond interactions. The structure shows a pattern of hydrogen-bond interactions 190 
following the expected hierarchical order between the best donor13 (sulphonylbenzamide NH) and the 191 
best acceptor (amide CO) together with the second best donor (amide NH) and the second best acceptor 192 
(sulphonylbenzamide CO) with an alternate amide/sulphonylamide supramolecular synthon (Figure 5). 193 
Ribbons are connected through weak CH···π interactions between a methoxy group and an aromatic 194 
ring (Cmethoxy−H···π centroid distance of 3.20 Å), Figure 6a and between two aromatic rings 195 
(Carene−H···π centroid distance of 2.65 Å), Figure 6b. 196 
3.3.2. Zafirlukast Acetonitrile Solvate. ZF acetonitrile solvate crystallizes with one molecule of ZF and 197 
one of acetonitrile in the asymmetric unit. Interestingly, no hydrogenbonding chains or ribbons are 198 
formed but discrete dimers of ZF molecules linked through a combination of amide−amide hydrogen-199 
bond interactions between the best donor (sulphonylbenzamide NH) and the best acceptor (amide CO) 200 
groups together with weak CH···π interactions involving the methoxy groups. Two molecules of 201 
acetonitrile surround each ZF dimer forming strong hydrogen bonds with the second best donor groups 202 
of ZF (amide NH) conferring extra stability to the selfassembled dimers (Figure 7). 203 
3.3.3. Zafirlukast Butanol Solvate. ZF butanol solvate also crystallizes with one molecule of ZF and one 204 
of butanol in the asymmetric unit. Infinite chains of ZF molecules are formed through strong hydrogen 205 
bonds but in a very different way with respect to the anhydrous Form X. Butanol molecules establish 206 
hydrogen bonds simultaneously with the best donor and the best acceptor of ZF leaving free the second 207 
best donor and the second best acceptor to form chains of self-assembled ZF molecules, Figures 8 and 9. 208 
Layers are interconnected through weak CH···π interactions involving different protons of the 209 
methylindole group of ZF, (Carene−H···π centroid distance of 2.84 and 3.20 Å), Figure 10, an 210 
interaction not observed in the other forms of ZF. 211 
3.3.4. Cocrystal Zafirlukast/Piperazine (2:1). In the crystal structure, different supramolecular synthons 212 
are observed with respect to the other structures of ZF. The main difference is that the oxygens of the 213 
benzenesulphonyl groups are involved in hydrogen bonds with the NH proton of the amide moiety. Very 214 
interestingly, this amide group has an infrequent cis conformation. It is well-known that acyclic 215 
secondary amides are usually found in the most stable trans amide conformation; however there is 216 
literature evidence that the equilibrium toward the less stable cis conformation can occur when strong 217 
noncovalent interactions are present.14 For example, many proteins have amino acid residues in a cis 218 
conformation because C−H···π interactions are able to stabilize them.15 Moreover, it has been observed 219 
that the replacement of the N-alkyl substituent of a secondary amide by a phenyl group tends to increase 220 
the stability of the cis confomer.16 221 
Although piperazine is a molecule which plays important roles in several fields, such as enzyme 222 
inhibitors,17 liquid crystalline compounds18 or recreative drugs,19 only 12 crystal structures of 223 
piperazine in neutral form have been described so far.20 224 
In the cocrystal structure, the piperazine resides on a crystallographic inversion center and has the most 225 
stable chair conformation with NH protons in the equatorial positions. Each piperazine occupies the 226 
space formed by four ZF molecules with six H-bond donors pointing to the center of the cavity. Since 227 
the piperazine has two strong donor and two acceptor groups, its location into the cavity is held by a 228 
favorable balance between attractive and repulsive interactions with the six donor groups, Figure 12. 229 
3.4. Polymorphism of the Piperazine Cocrystal. Usually the most stable polymorphic modification is 230 
used in a marketed formulation. Overlooking the most stable polymorph may cause failure of a 231 
marketed product, because a phase transformation during storage can occur. A lateappearing stable 232 
polymorph can have a negative impact on development timelines21 as it has been shown by many 233 
reviews written on disappearing polymorphs.22 However, metastable forms may survive years if a high 234 
activation energy barrier has to be overcome in moving from the metastable form to the stable one. In 235 
the present case, some information about the stability and interconversion of the different ZF/piperazine 236 
cocrystals has been obtained. 237 
Five different forms of a multicomponent crystal formed by ZF and piperazine were discovered and 238 
isolated during the cocrystal screen: three forms with 1:1 stoichiometry (including a toluene solvate) and 239 
two forms with 2:1 stoichiometry. Figures 13 and 14 show the PXRD patterns of these five forms. 240 
As it has been described previously, only one of the two 2:1 cocrystal structures has been solved by 241 
single crystal XRD (Form A). However, the cell of the second polymorph (Form B) has been indexed 242 
(Figures of Merit of M: 25; F: 75. Unit cell parameters were refined by Le Bail fit23 using Fullprof 243 
program24 with a final χ2: 4.75), being also triclinic with similar cell dimensions and a slightly bigger 244 
volume (Figure 15 and Table 1). The higher density of Form A suggests that Form B is metastable at 245 
room temperature with respect to Form A, which was confirmed through solvent mediated 246 
transformation experiments: a mixture of Form A and Form B transforms into pure Form A after 72 h 247 
slurring in ethanol. 248 
But in order to complete the stability landscape, it is necessary to define whether the two forms are 249 
monotropically (one form is more stable than the other at any temperature) or enantiotropically (a 250 
transition temperature exists, where the stability order is reversed) related. DSC provides information 251 
about the melting temperature and the enthalpy of fusion of each form, which can be analyzed to define 252 
the relative stability between the two polymorphs. Thus, according to the so-called “heat-of-fusion 253 
rule”,25 Forms A and B are monotropically related (Form A is thermodynamically more stable than 254 
Form B at all temperatures up to the melting point) since Form A has the highest melting point and 255 
highest enthalpy of fusion (Table 2). 256 
On the other hand, the three 1:1 cocrystal forms tend to transform into the apparently more stable 2:1 257 
cocrystal and reduce the content of piperazine. For instance, Form C transforms into Form B after 6 258 
months at room temperature, and Forms D and E transform into Form B after 48 h slurring in water. 259 
Interestingly, when Form C is heated up it shows a loss on weight around 120 °C, and the melting of the 260 
2:1 cocrystal is observed, Figure 16. PXRD analysis confirms Form B is obtained. The fact that the DSC 261 
curves of the two polymorphs of the 2:1 cocrystals do not show the loss of piperazine until they melt 262 
suggests that there are two different crystallographic positions of the piperazine molecules in the 263 
structures of the 1:1 cocrystals, one labile enough to be disturbed upon heating and another strong 264 
enough to resist until melting at very high temperature. Unfortunately, since the crystal structure of any 265 
of the 1:1 cocrystals remains elusive this hypothesis is rather speculative. 266 
  267 
4. CONCLUSION 268 
 269 
A spectroscopist from Chicago (Walter McCrone) said in 1965 that the number of polymorphs a 270 
compound has is proportional to the amount of money and time that has been spent investigating the 271 
molecule.26 In the case of cocrystals this is also true, but pharmaceutical cocrystal development is by no 272 
means a straightforward process. To engineer the right cocrystal requires not only a deep knowledge of 273 
the intermolecular forces present in the cocrystal and crystal packing, but also finding the right set of 274 
conditions for which the sum of the chemical potentials of the components in solution is greater than in 275 
the solid phases, implying prediction of activity coefficients and knowledge of ternary solubility data.27 276 
High throughput screening is usually performed trying to maximize the potential to find new cocrystals, 277 
but given the number of variables involved it is difficult to cover the full landscape. 278 
From the pharmaceutical point of view spending money and time in the discovery of new cocrystals will 279 
only make sense if the new cocrystal has some kind of advantage, of clinical relevance (i.e., improved 280 
human pharmacokinetics through changes in solubility and/or dissolution rates, a better toxicity profile 281 
(lower Cmax/Cmin), improved solid state properties such as stability, crystalline form/habit, 282 
processability or developability), over the parent API itself. At present, the predictability of the physical 283 
chemistry properties of a cocrystal is still far from ideal,28 and the impact of these physicochemical 284 
properties changes on the pharmacokinetics is still not well understood because the amount of cocrystal 285 
PK data in the literature is insufficient to do a proper quantitative analysis.28  286 
A first step in the ultimate goal of understanding the cocrystal behavior in vivo, and hence, being able to 287 
predict it, is the generation of new cocrystals (properly characterized) of medicines already on the 288 
market, so all the data generated can be openly shared within the scientific community. With this 289 
intention we have explored thoroughly the solid form landscape of ZF. The four new forms found 290 
(anhydrous, solvate, and cocrystal forms) show a rich diversity of intermolecular interactions. Thus, it is 291 
not surprising that the first reported cocrystal of this important API exists in at least five different forms 292 
with two stoichiometries, converting ZF in another example of the increasing list of compounds capable 293 
to form polymorphic cocrystals.29 These new forms have been carefully characterized and will be the 294 
subject of a future investigation addressing the relationships between physical chemistry properties and 295 
the cocrystal pharmacokinetics. These results will be the subject of future contributions. 296 
 297 
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Legends to figures 358 
 359 
Figure 1 Zafirlukast (ZF). 360 
 361 
Figure 2. PXRD of the new solvates and anhydrous form of ZF. 362 
 363 
Figure 3 DSC and TGA of the ZF ACN solvate. DSC curve of the anhydrous form is shown for 364 
comparison. 365 
 366 
Fig. 4 DSC and TGA of the ZF BuOH solvate. DSC curve of the anhydrous form is shown for 367 
comparison. 368 
 369 
Figure 5. Ribbons of self-assembled molecules of ZF in Form X. 370 
 371 
Figure 6. (a) Cmethoxy−H···π interaction and (b) Carene−H···π interaction in Form X of ZF. 372 
 373 
Figure 7. Self-assembled dimers of ZF stabilized by peripheral acetonitrile−amide interactions in ZF 374 
acetonitrile solvate (some hydrogens have been omitted for clarity). 375 
 376 
Figure 8. Hydrogen bond interactions established between butanol and ZF molecules in the butanol 377 
solvate. 378 
 379 
Figure 9. Chains of hydrogen-bonded molecules of ZF in the butanol solvate. 380 
 381 
Figure 10. CH···π interactions observed in the butanol solvate. 382 
 383 
Figure 11. Chains of ZF molecules in the piperazine cocrystal. 384 
 385 
Figure 12. Cavity occupied by the piperazine molecule in the cocrystal (hydrogens and fragments of the 386 
ZF molecules have been omitted for clarity). 387 
 388 
Figure 13. PXRD patterns of the five ZF/piperazine cocrystals. 389 
 390 
Figure 14. PXRD patterns of the two 2:1 ZF/piperazine cocrystals. 391 
 392 
Figure 15. Le Bail fit of 2:1 ZF/piperazine cocrystal Form B. 393 
Figure 16. DSC and TGA traces of the 1:1 cocrystal Form C. 394 
 395 
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Table 3. Crystal Data and Structure Refinement Parameters for the Different Forms of ZF. 502 
 503 
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